Ibnsina Pharma Statistics

Total Valuation

Ibnsina Pharma has a market cap or net worth of EGP 6.47 billion. The enterprise value is 22.58 billion.

Market Cap	6.47B
Enterprise Value	22.58B

Important Dates

The last earnings date was Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Ibnsina Pharma has 1.01 billion shares outstanding.

Current Share Class	n/a
Shares Outstanding	1.01B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	26.01%
Owned by Institutions (%)	23.67%
Float	652.98M

Valuation Ratios

The trailing PE ratio is 17.91 and the forward PE ratio is 14.93.

PE Ratio	17.91
Forward PE	14.93
PS Ratio	0.13
PB Ratio	3.55
P/TBV Ratio	4.02
P/FCF Ratio	12.13
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.02, with an EV/FCF ratio of 42.33.

EV / Earnings	62.49
EV / Sales	0.47
EV / EBITDA	11.02
EV / EBIT	12.37
EV / FCF	42.33

Financial Position

The company has a current ratio of 1.00, with a Debt / Equity ratio of 9.34.

Current Ratio	1.00
Quick Ratio	0.66
Debt / Equity	9.34
Debt / EBITDA	8.30
Debt / FCF	31.92
Interest Coverage	1.21

Financial Efficiency

Return on equity (ROE) is 27.60% and return on invested capital (ROIC) is 6.93%.

Return on Equity (ROE)	27.60%
Return on Assets (ROA)	5.09%
Return on Capital (ROIC)	6.93%
Revenue Per Employee	8.83M
Profits Per Employee	65,704
Employee Count	5,500
Asset Turnover	2.17
Inventory Turnover	8.42

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +137.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+137.78%
50-Day Moving Average	5.43
200-Day Moving Average	3.62
Relative Strength Index (RSI)	64.99
Average Volume (20 Days)	5,107,060

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ibnsina Pharma had revenue of EGP 48.55 billion and earned 361.37 million in profits. Earnings per share was 0.36.

Revenue	48.55B
Gross Profit	3.66B
Operating Income	1.83B
Pretax Income	497.27M
Net Income	361.37M
EBITDA	1.96B
EBIT	1.83B
Earnings Per Share (EPS)	0.36

Full Income Statement

Balance Sheet

The company has 914.94 million in cash and 17.03 billion in debt, giving a net cash position of -16.11 billion or -15.98 per share.

Cash & Cash Equivalents	914.94M
Total Debt	17.03B
Net Cash	-16.11B
Net Cash Per Share	-15.98
Equity (Book Value)	1.82B
Book Value Per Share	1.81
Working Capital	30.63M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 710.09 million and capital expenditures -176.61 million, giving a free cash flow of 533.48 million.

Operating Cash Flow	710.09M
Capital Expenditures	-176.61M
Free Cash Flow	533.48M
FCF Per Share	0.53

Full Cash Flow Statement

Margins

Gross margin is 7.55%, with operating and profit margins of 3.76% and 0.92%.

Gross Margin	7.55%
Operating Margin	3.76%
Pretax Margin	1.02%
Profit Margin	0.92%
EBITDA Margin	4.03%
EBIT Margin	3.76%
FCF Margin	1.10%

Dividends & Yields

Ibnsina Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	5.74%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	5.58%
FCF Yield	8.24%

Dividend Details

Stock Splits

The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.

Last Split Date	Jun 1, 2022
Split Type	Forward
Split Ratio	1.16666

Scores

Ibnsina Pharma has an Altman Z-Score of 2.24. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.24
Piotroski F-Score	n/a